Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-974-5 | CAS number: 12047-11-9
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity: the estimated DL50 value is higher than 2000 mg/kg bw.
Acute inhalation toxicity: no DL50 value may be estimated. The substance can cause adverse effects to the lungs.
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- LD50
- Value:
- 2 001 mg/kg bw
Additional information
Study results indicate that the barium hexaferrite does not cause any acute toxic effect when it is administered at 2000 mg/kg by oral route.
Study results indicate that the inhaled barium hexaferrite powder can be retained inside the lungs for a long time period even after an acute inhalation exposure. As described in the Kosova et al (1972) paper, the substance can cause adverse local effects (as fibrosis) which are manifested after a long time period.
Read-across justification: data regarding barium hexaferrite are provided as key study; at the same time further literature data concerning other substances, which are deemed closely similar, are reported as supporting studies.
Justification for classification or non-classification
According to Directive 67/548/EEC and to Regulation (EC) n. 1272/2008, the study results indicate that the substance should not be classified for acute oral toxicity.
According to Directive 67/548/EEC and to Regulation (EC) n. 1272/2008, study results indicate that the substance should not be classified for acute toxicity by inhalation route in terms of mortality, but requires STOT SE cat 2 H371 for its effects on lungs by inhalation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
